Release
📈 Stocks
Castle Biosciences TissueCypher Data Validates Barrett's Esophagus Risk
(3 days ago)
New clinical data confirms Castle Biosciences' TissueCypher platform provides critical risk stratification for Barrett's esophagus patients, potentially accelerating clinical adoption.